Key facts
- This page summarizes Daniel E. Geffken's Form 3 filing for PHOENIX BIOTECH ACQUISITION CORP. (CERO).
- 0 reported transactions and 0 derivative rows are listed below.
- Accepted by SEC: 05 Oct 2021, 18:53.
Daniel E. Geffken - 05 Oct 2021 Form 3 Insider Report for PHOENIX BIOTECH ACQUISITION CORP. (CERO)
- Reporting relationship
- Chief Financial Officer
- Issuer ticker
- CERO
- Reported as of
- 05 Oct 2021
- Net transaction value
- $0
- SEC form
- 3
- Accepted by SEC
- 05 Oct 2021, 18:53:43 UTC
- Prior SEC filing
- 17 Jun 2021
- Next SEC filing
- 12 Oct 2021
- Source filing
- View source filing
- Reporting owner signature
- /s/ Chris Ehrlich, as attorney-in-fact
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Daniel E. Geffken filed Form 3 for PHOENIX BIOTECH ACQUISITION CORP. (CERO) on 05 Oct 2021.
Change
- Previous filing in this sequence was filed on 17 Jun 2021.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Official SEC source
View source filing
Ownership activity is grounded in SEC Form 3 disclosures.
Additional SEC filing notes
Filing notes and footnotes
Ownership status
The filing reports no beneficially owned securities.
SEC remarks
Exhibit 24 - Power of Attorney